The White House Office of Management and Budget last week completed its review of FDA’s draft guidance on quality considerations for clinical research on cannabis. Once issued, the draft will be the first agency guidance focused specifically on cannabis, coming as House appropriators again propose funding the FDA’s long-awaited CBD regulatory framework . OMB completed its review of the draft document Thursday (July 2), just slightly more than a month after FDA sent the draft for review . FDA has...